PATH vs XFOR · P/E 19, rev $1.61B vs rev $2.6M
Uipath Inc (PATH) versus X4 Pharmaceuticals Inc (XFOR) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
X4 Pharmaceuticals Inc (XFOR) is a biotechnology company listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported XFOR revenue for 2024-12-31 was $2.6M. Net income was -$37.5M. XFOR currently screens at market cap $382.0M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. XFOR currently screens at market cap $382.0M.
Not investment advice. Open the PATH and XFOR stock pages for the full models.
Not investment advice.